His Royal Highness Prince Salman bin Hamad Al Khalifa, Crown Prince and Prime Minister, has underscored Bahrain’s recent medical milestone – the successful treatment of the world’s first sickle cell disease patient outside the US using Casgevy.
This breakthrough highlights the kingdom’s commitment to delivering cutting-edge medical services to citizens, he said.
Casgevy (exagamglogene autotemcel) is a CRISPR-based gene-editing therapy that utilises bone marrow transplantation technology.
HRH Prince Salman praised the accomplishment as he met Bahrain Society for Sickle Cell Disease chairman Zakaria Al Khadim and board members, at Gudaibiya Palace yesterday.
He reaffirmed that the well-being of citizens remains the kingdom’s top priority.
HRH the Crown Prince and Prime Minister emphasised the importance of sustainable healthcare development, ensuring services meet the aspirations of Bahraini citizens, in line with the visionary leadership of His Majesty King Hamad.
He commended the dedication of the national workforce, highlighting their significant contributions to the kingdom’s development, particularly in the healthcare sector. He reiterated Bahrain’s commitment to advancing its medical services by enhancing efficiency, sustainability and access to cutting-edge treatments.
Mr Al Khadim expressed his gratitude for HRH Prince Salman’s continued support in strengthening Bahrain’s healthcare sector.
Finance and National Economy Minister Shaikh Salman bin Khalifa Al Khalifa and Health Minister Dr Jalila Al Sayyed also attended the meeting.
Top stories for today:
Victim identified as school pupil
King establishes Bahrain Space Agency
Bahrain gears up to tackle rain and mosquito menace
&uuid=(email))